PubRank

D A Lawrence

Author PubWeight™ 180.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999 7.69
2 WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 1998 3.73
3 Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000 3.45
4 Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. J Clin Invest 1975 3.39
5 The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996 3.34
6 Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998 2.98
7 Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984 2.76
8 Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun 1985 2.75
9 Regulation of methionine synthesis in Salmonella typhimurium: mutants resistant to inhibition by analogues of methionine. Genetics 1968 2.62
10 Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001 2.40
11 Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984 2.22
12 Strand-selective repair of DNA damage in the yeast GAL7 gene requires RNA polymerase II. J Biol Chem 1992 1.94
13 Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000 1.90
14 Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun 1986 1.90
15 Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999 1.88
16 Further study of beta-TGFs released by virally transformed and non-transformed cells. Int J Cancer 1985 1.77
17 Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995 1.73
18 Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem 1984 1.59
19 Preferential repair of DNA damage on the transcribed strand of the human metallothionein genes requires RNA polymerase II. Mutat Res 1991 1.58
20 Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001 1.58
21 Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. Cancer Res 1984 1.51
22 The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost 2011 1.51
23 Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990 1.50
24 Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997 1.47
25 Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. Arthritis Rheum 1995 1.44
26 Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 1998 1.42
27 The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999 1.40
28 Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2000 1.40
29 Cytophilic properties of IgA to human neutrophils. Adv Exp Med Biol 1974 1.38
30 Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol 1989 1.38
31 The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994 1.36
32 Characterization of an IgE receptor isolated from cultured B-type lymphoblastoid cells. J Immunol 1978 1.23
33 Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol 1995 1.23
34 Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006 1.21
35 Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol 1996 1.17
36 A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 1995 1.16
37 Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 1999 1.16
38 Regulation of the methionine-specific aspartokinase and homoserine dehydrogenase of Salmonella typhimurium. J Gen Microbiol 1968 1.13
39 Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994 1.10
40 Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol 2000 1.08
41 2,4-Dinitrophenyl receptors on mouse thymus and spleen cells. J Exp Med 1973 1.07
42 Stimulation of murine lymphocyte responses by cations. Cell Immunol 1986 1.06
43 Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum 1995 1.06
44 Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF. Int J Cancer 1989 1.05
45 Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem 1992 1.05
46 Susceptibility of C5-deficient mice to listeriosis: modulation by Concanavalin A. Cell Immunol 1978 1.04
47 Identification and activation of latent transforming growth factor beta. Methods Enzymol 1991 1.04
48 Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry 1986 1.04
49 Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation 2001 1.04
50 Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980 1.03
51 Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem 1995 1.02
52 Regulation of the methionine feedback-sensitive enzyme in mutants of Salmonella typhimurium. J Bacteriol 1972 1.01
53 Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis. Am J Pathol 2001 0.99
54 The serpin-proteinase complex revealed. Nat Struct Biol 1997 0.96
55 Level of methionyl-tRNA synthetase in merodiploids of Escherichia coli K12. Eur J Biochem 1970 0.94
56 Measurement of macrophage adherence and spreading with weak electric fields. J Immunol Methods 1990 0.94
57 In vivo the environmental pollutants lead and mercury induce oligoclonal T cell responses skewed toward type-2 reactivities. Cell Immunol 1997 0.94
58 Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 1997 0.94
59 A histological comparison of adenomatous and hyperplastic parathyroid glands. J Clin Pathol 1978 0.93
60 Serpin conformational change in ovalbumin. Enhanced reactive center loop insertion through hinge region mutations. Biochemistry 1997 0.93
61 Cells transformed by Rous sarcoma virus release transforming growth factors. J Cell Physiol 1982 0.93
62 New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environ Health Perspect 1999 0.92
63 Metal-induced modulation of nitric oxide production in vitro by murine macrophages: lead, nickel, and cobalt utilize different mechanisms. Toxicol Appl Pharmacol 1996 0.92
64 Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost 2010 0.92
65 Differential in vitro effects of physiological and atmospheric oxygen tension on normal human peripheral blood mononuclear cell proliferation, cytokine and immunoglobulin production. Int J Immunopharmacol 1996 0.91
66 Lead potentiates cytokine- and glutamate-mediated increases in permeability of the blood-brain barrier. Neurotoxicology 1998 0.91
67 Differential effects of concanavalin A and phytohemagglutinin on murine immunity. Suppression and enhancement of humoral immunity. Cell Immunol 1977 0.91
68 Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2004 0.89
69 Modulation of T-cell functions. I. Effect of 2-mercaptoethanol and macrophages on T-cell proliferation. Cell Immunol 1980 0.89
70 Mechanisms for the cytotoxicity of cysteamine. Toxicol Sci 2001 0.89
71 Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res 2012 0.89
72 Sarcoidosis associated with Crohn's disease of ileum, mouth and oesophagus. J R Soc Med 1983 0.89
73 Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int 2006 0.89
74 Heavy metal modulation of lymphocyte activities. 1. In vitro effects of heavy metals on primary humoral immune responses. Toxicol Appl Pharmacol 1981 0.89
75 The efficiency of maternal transfer of lead and its influence on plasma IgE and splenic cellularity of mice. Toxicol Sci 2000 0.88
76 Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995 0.88
77 Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 1993 0.88
78 The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine. J Biol Chem 1991 0.87
79 Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem 1995 0.87
80 Differences in the occurrence of hypertension among (NZB X NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol 1984 0.87
81 Differential effects of lead and cAMP on development and activities of Th1- and Th2-lymphocytes. Toxicol Sci 1998 0.87
82 Determination of glutathione in lymphocytes and possible association of redox state and proliferative capacity of lymphocytes. Biochem J 1981 0.87
83 Growth stimulation of murine fibroblasts by TGF-beta1 depends on the expression of a functional p53 protein. Oncogene 1999 0.87
84 Suppression of methionyl transfer RNA synthetase mutants of Salmonella typhimurium by methionine regulatory mutations. J Gen Microbiol 1970 0.87
85 Reduced glutathione is highly expressed in white matter and neurons in the unperturbed mouse brain--implications for oxidative stress associated with neurodegeneration. Brain Res 2009 0.87
86 The heavy metal lead exhibits B cell-stimulatory factor activity by enhancing B cell Ia expression and differentiation. J Immunol 1990 0.87
87 Fluorometric quantitation of cellular and nonprotein thiols. Anal Biochem 1986 0.87
88 Interleukin-12 promotes enhanced resistance to Listeria monocytogenes infection of lead-exposed mice. Toxicol Appl Pharmacol 1997 0.86
89 Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996 0.86
90 Immunomodulation by metals. Fundam Appl Toxicol 1994 0.86
91 Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med 1998 0.86
92 Lead, a major environmental pollutant, is immunomodulatory by its differential effects on CD4+ T cells subsets. Toxicol Appl Pharmacol 1991 0.86
93 Effect of lead on macrophage function. J Leukoc Biol 1988 0.86
94 Neuronal cell death and reactive oxygen species. Cell Mol Neurobiol 2000 0.86
95 Murine T-cell preparations: radiosensitivity of helper activity. Cell Immunol 1978 0.85
96 Modulation of T-cell function. II. Chemical basis for the involvement of cell surface thiol-reactive sites in control of T-cell proliferation. Cell Immunol 1981 0.85
97 The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A. J Biol Chem 1995 0.85
98 The spatial coding strategies of one-year-old infants in a locomotor search task. Child Dev 1995 0.84
99 Lead inhibits nitric oxide production in vitro by murine splenic macrophages. Toxicol Appl Pharmacol 1995 0.84
100 Inhibition of human T lymphoblast proliferation by hydroquinone. Toxicol Appl Pharmacol 1996 0.84
101 Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 2000 0.84
102 In vivo and in vitro effects of lead on humoral and cell-mediated immunity. Infect Immun 1981 0.84
103 Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst 2000 0.84
104 Genetic mapping of GLCLC, the human gene encoding the catalytic subunit of gamma-glutamyl-cysteine synthetase, to chromosome band 6p12 and characterization of a polymorphic trinucleotide repeat within its 5' untranslated region. Cytogenet Cell Genet 1996 0.83
105 Antagonistic action of RU38486 on the activity of transforming growth factor-beta in fibroblasts and lymphoma cells. J Steroid Biochem 1988 0.83
106 Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost 2009 0.83
107 Differential effects of concanavalin A and phytohemagglutinin on murine immunity. Suppression and enhancement of cell-mediated immunity. Cell Immunol 1977 0.83
108 Glutathione depletion in human T lymphocytes: analysis of activation-associated gene expression and the stress response. Toxicol Appl Pharmacol 1995 0.82
109 The heavy metal lead modulates the expression of both TNF-alpha and TNF-alpha receptors in lipopolysaccharide-activated human peripheral blood mononuclear cells. J Leukoc Biol 1996 0.82
110 TGF-beta-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 1991 0.82
111 Adrenocorticotropin-independent hypercortisolemia and testicular tumors in a patient with a pituitary tumor and gigantism. J Clin Endocrinol Metab 1982 0.82
112 The inhibitory effects of N-ethylmaleimide, colchicine and cytochalasins on human T-cell functions. Int J Immunopharmacol 1989 0.82
113 Immunotoxic effects of inorganic lead on host resistance of mice with different circling behavior preferences. Brain Behav Immun 2000 0.81
114 Extracellular metallothionein effects on lymphocyte activities. Mol Immunol 1990 0.81
115 Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism. J Thromb Haemost 2014 0.81
116 Altered serum cytokine and immunoglobulin levels in the workers exposed to antimony. Hum Exp Toxicol 1999 0.80
117 Heavy metal modulation of lymphocyte activities--II. Lead, an in vitro mediator of B-cell activation. Int J Immunopharmacol 1981 0.80
118 Flow cytometric measurements of neuronal death triggered by PCBs. Neurotoxicology 1997 0.80
119 Immunologic detection of the cellular receptor for urokinase plasminogen activator. Clin Immunol Immunopathol 1994 0.80
120 Sequential analysis of biomarkers in cerebrospinal fluid and serum during invasive meningococcal disease. Eur J Clin Microbiol Infect Dis 2009 0.80
121 Serum IgE elevation correlates with blood lead levels in battery manufacturing workers. Hum Exp Toxicol 2004 0.80
122 Influence of hydroxyethyl starch on humoral and cell-mediated immune responses in mice. Transfusion 1985 0.80
123 Modulation of T-helper cell populations: potential mechanisms of respiratory hypersensitivity and immune suppression. Toxicol Appl Pharmacol 1997 0.79
124 Phospholipid metabolism of lymphocytes with inhibited glutathione synthesis using L-buthionine-S,R-sulfoximine. Free Radic Biol Med 1995 0.79
125 Antigenic modulation of the cytophilic binding of guinea-pig IgG and IgM antibodies to homologous macrophages. Immunology 1979 0.79
126 Role of endogenous cytokines in endotoxin- and interleukin-1-induced pulmonary inflammatory response and oxygen tolerance. Am J Respir Cell Mol Biol 1995 0.79
127 Oxidatively stressed lymphocytes remain in G0/G1a on mitogenic stimulation. J Biochem Toxicol 1990 0.79
128 Assessment of immunotoxicity by multiparameter flow cytometry. Fundam Appl Toxicol 1997 0.79
129 Effects of 2-mercaptoethanol and buthionine sulfoximine on cystine metabolism by and proliferation of mitogen-stimulated human and mouse lymphocytes. Int J Immunopharmacol 1992 0.79
130 Differential production of interleukin-6 in the brain and spleen of mice treated with lipopolysaccharide in the presence and absence of lead. J Toxicol Environ Health A 1998 0.78
131 Lead-induced alterations of in vitro bone marrow cell responses to colony stimulating factor-1. J Leukoc Biol 1989 0.78
132 Developmental toxicity of a triazole fungicide: consideration of interorgan communication. Toxicol Sci 2001 0.78
133 Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development. Am J Pathol 1999 0.78
134 Relationships between IFNgamma, IL-6, corticosterone, and Listeria monocytogenes pathogenesis in BALB/c mice. Cell Immunol 2001 0.78
135 Both pro-uPA and uPA: PAI-1 complex bind to the alpha 2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor. Ann N Y Acad Sci 1994 0.78
136 Evidence for a novel growth factor in Xenopus oocytes. Biochem Biophys Res Commun 1989 0.78
137 Sex effects of interleukin-6 deficiency on neuroinflammation in aged C57Bl/6 mice. Brain Res 2010 0.77
138 Residual activation events functional after irradiation of mouse splenic lymphocytes. Radiat Res 1991 0.77
139 Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells. Int J Immunopharmacol 1998 0.77
140 Analysis of lead effects on in vivo antibody-mediated immunity in several mouse strains. Toxicol Appl Pharmacol 1986 0.77
141 Differential lymphocyte growth-modifying effects of oxidants: changes in cytosolic Ca+2. Toxicol Appl Pharmacol 1989 0.77
142 Four sulfhydryl-modifying compounds cause different structural damage but similar functional damage in murine lymphocytes. Chem Biol Interact 1988 0.77
143 Cyclic AMP levels and 2-deoxyglucose uptake in cells transformed by temperature-sensitive class T mutants of Rous sarcoma virus. Virology 1977 0.77
144 Inhibition of interleukin-2 production in the human T cell line JURKAT by nonpolar maleimides. Toxicol Appl Pharmacol 1991 0.77
145 Drosophila cell extracts contain a TGF-beta-like activity. Biochem Biophys Res Commun 1990 0.77
146 Novel approaches to thrombolysis based on modulation of endogenous fibrinolysis. Coron Artery Dis 1998 0.77
147 Regulation of HLA-DR and invariant chain expression by human peripheral blood mononuclear cells with lead, interferon-gamma, or interleukin-4. Cell Immunol 1996 0.77
148 Thrombin increases expression of urokinase receptor by activation of the thrombin receptor. Invest Ophthalmol Vis Sci 1995 0.77
149 The dietary supplement ephedrine induces beta-adrenergic mediated exacerbation of systemic lupus erythematosus in NZM391 mice. Lupus 2005 0.77
150 Stimulation of antibody production to the hapten 2,4-dinitrobenzene by affinity labeled murine lymphoid cells. I. Ability of affinity labeled murine lymphoid cells to activate the in vivo immune response. J Exp Med 1974 0.77
151 Cell surface and cell cycle analysis of metal-induced murine T cell proliferation. Eur J Immunol 1986 0.77
152 Vitamin E enhances Ca(2+)-mediated vulnerability of immature cerebellar granule cells to ischemia. Free Radic Biol Med 1998 0.76
153 Effects of murine endotoxemia on lymphocyte subsets and clearance of staphylococcal pulmonary infection. Folia Microbiol (Praha) 2006 0.76
154 The effect of metals on IL-2-related lymphocyte proliferation. Int J Immunopharmacol 1988 0.76
155 Immunomodulation of in vitro antigen presentation by cations. Toxicol Appl Pharmacol 1988 0.76
156 Lead influences translational or posttranslational regulation of Ia expression and increases invariant chain expression in mouse B cells. J Biochem Toxicol 1991 0.76
157 Modification of lipoprotein patterns and retardation of atherogenesis by a fish oil supplement to a hyperlipidemic diet for swine. Atherosclerosis 1989 0.76
158 Altered complex formation between p21waf, p27kip and their partner G1 cyclins determines the stimulatory or inhibitory transforming growth factor-beta1 growth response of human fibroblasts. Int J Oncol 1999 0.75
159 Tertiary hyperparathyroidism with adenoma formation after renal transplantation. Br Med J 1978 0.75
160 Lipopolysaccharide and interleukin-6 enhance lead entry into cerebellar neurons: application of a new and sensitive flow cytometric technique to measure intracellular lead and calcium concentrations. Neurotoxicology 1998 0.75
161 Differential immune responses in mice with left- and right-turning preference. J Neuroimmunol 1999 0.75
162 Further studies of the action of methionyl adenylate on chick embryo fibroblasts. Biochim Biophys Acta 1977 0.75
163 Transforming growth factors--an overview. Biol Cell 1985 0.75
164 Cyclization of T-cell helper activity. Cell Immunol 1980 0.75
165 In utero management of hydrops fetalis caused by critical aortic stenosis. Am J Perinatol 1997 0.75
166 N-ras mRNA expression is unaffected in glutathione-depleted cells of hematopoietic origin. Cancer Lett 1995 0.75
167 Transdifferentiated embryonic neuroretina cells: an in vitro system to study crystallin aggregation process. Exp Eye Res 1987 0.75
168 Differential uptake of 2-fluoro-2-deoxyglucose by normal and transformed chicken and mouse fibroblasts as a function of glucose concentration. Eur J Cancer Clin Oncol 1982 0.75
169 Immunochemical analysis of the basic immunoglobulin in papular mucinosis. Immunochemistry 1972 0.75
170 Chemically and virally transformed cells able to grow without anchorage in serum-free medium: evidence for an autocrine growth factor. J Cell Physiol 1987 0.75
171 Inhibition of human T cell responses by hydrogen peroxide. Pharmacol Ther 1988 0.75
172 Simultaneous presentation of papillary carcinoma of thyroid in a father and son. Br J Surg 1983 0.75
173 Bifunctional activity of transforming growth factor type beta on the growth of NRK-49F cells, normal and transformed by Kirsten murine sarcoma virus. J Cell Physiol 1988 0.75
174 Hydroquinone resistance in a murine myeloblastic leukemia cell line. Involvement of quinone reductase and glutathione-dependent detoxification in nonclassical multidrug resistance. Biochem Pharmacol 1996 0.75
175 In vitro effects of hydroquinone, benzoquinone, and doxorubicin on mouse and human bone marrow cells at physiological oxygen partial pressure. Toxicol Appl Pharmacol 1994 0.75
176 An ounce of prevention: checking up on buckling up. Va Med 1979 0.75
177 2-Mercaptoethanol-dependent lipopolysaccharide-responsive B cells in nylon-wool-fractionated spleen cell preparations. Scand J Immunol 1985 0.75
178 Stimulation of growth of serum-deprived chick embryo fibroblasts by 3',5'-phosphodiesterase. Exp Cell Res 1975 0.75
179 T-cell chronic lymphocytic leukaemias and T-cell lymphoma-leukaemia: heterogeneity and anomalous cell markers. Scand J Haematol 1986 0.75
180 Differential inhibition of human T-lymphocyte activation by maleimide probes. Cell Immunol 1986 0.75
181 The American Board of Family Practice: phoenix or ostrich in 1983? J Fam Pract 1979 0.75
182 The allogeneic effect: the mechanism of allosuppression by Lyt-1, Ia- T cells. J Immunol 1984 0.75
183 Isolation and characterization of the basic, diagnostic IgG globulin in the rare gammopathy, papular mucinosis. Prep Biochem 1971 0.75
184 TNP-modified syngeneic cells enhance immunoregulatory T cell activities similar to allogeneic effects. J Immunol 1982 0.75
185 Nucleotide changes in oxidatively stressed lymphocytes. J Biochem Toxicol 1995 0.75
186 Mercury (Hg 2+) enhances the depressant effect of kainate on Ca-inactivated potassium current in telencephalic cells derived from chick embryos. Toxicol Appl Pharmacol 1996 0.75
187 Hexose uptake enhancing factor released from Rous sarcoma cells. J Cell Physiol 1980 0.75
188 The effects of interleukin-1 beta and tumor necrosis factor-alpha on in vitro colony formation by human hematopoietic progenitor cells exposed to doxorubicin or hydroquinone. Exp Hematol 1995 0.75
189 Blindness in South Australian kangaroos. Aust Vet J 1996 0.75
190 Stimulation of antibody production to the hapten, 2,4-dinitrobenzene by affinity-labeled murine lymphoid cells. II. Suppressive activity of an excess of thymocytes. Cell Immunol 1976 0.75
191 Transforming growth factor-beta 1 enhances serum-induced dephosphorylation of the P53 protein in cell lines growth-inhibited by this factor. Growth Factors 1994 0.75
192 Nicotine chewing gum and smoking cessation. J Fam Pract 1988 0.75